Table 4.
Distribution of cleaved embryos recorded at different time points after microinjection of CDC5L antibody into MII oocytes followed by parthenogenetic activation
Control, without microinjection; NC, microinjected negative control; siCDC5L, microinjected CDC5L siRNAs. a-b and A-B indicate significant differences at p < 0.05 and p < 0.01 levels within the same subcolumns, respectively.
| Group | No. embryos | No. 1-cell | No. 2-cell | No. 3-cell | No. 4-cell | No. 5-cell | |
|---|---|---|---|---|---|---|---|
| % ± S.D. | |||||||
| 20 h | Control | 148 | 88 (59.9 ± 6.5%) | 51 (34.3 ± 0.8%) | 4 (2.7 ± 1.0%) | 0 | 0 |
| IgG | 150 | 85 (57.2 ± 2.8%) | 51 (34.1 ± 5.3%) | 8 (5.0 ± 4.4%) | 0 | 0 | |
| Anti-CDC5L | 140 | 90 (64.3 ± 2.2%) | 32 (22.9 ± 1.1%) | 4 (2.9 ± 1.2%) | 0 | 0 | |
| 26 h | Control | 147 | 37 (26.1 ± 10.5%)a | 78 (53.4 ± 3.8%)a | 13 (8.7 ± 1.1%) | 1 (0.6 ± 1.1%) | 0 |
| IgG | 150 | 39 (26.2 ± 6.6%)a | 79 (52.8 ± 2.6%)a | 15 (10.0 ± 0.9%) | 3 (2.0 ± 2.0%) | 0 | |
| Anti-CDC5L | 139 | 55 (39.8 ± 10.8%)b | 53 (38.0 ± 3.5%)b | 9 (6.5 ± 2.4%) | 1 (7.6 ± 1.3%) | 0 | |
| 39 h | Control | 144 | 15 (10.8 ± 6.4%) | 31 (21.9 ± 8.7%) | 40 (28.5 ± 6.5%) | 40 (26.8 ± 9.2%)A | 7 (4.7 ± 1.8%) |
| IgG | 147 | 14 (9.7 ± 3.2%) | 32 (22.0 ± 6.4%) | 41 (27.9 ± 2.4%) | 40 (26.9 ± 8.0%)A | 6 (4.2 ± 2.4%) | |
| Anti-CDC5L | 138 | 23 (16.7 ± 1.0%) | 32 (23.7 ± 12.2) | 37 (26.6 ± 7.3%) | 18 (12.9 ± 4.9%)B | 4 (2.9 ± 2.5%) | |
| 48 h | Control | 144 | 14 (10.2 ± 7.4%) | 31 (21.7 ± 6.7%) | 37 (25.7 ± 0.2%) | 46 (31.5 ± 4.3%) | 10 (6.9 ± 2.7%) |
| IgG | 147 | 11 (7.7 ± 3.7%) | 30 (20.8 ± 8.9%) | 38 (15.5 ± 6.1%) | 46 (31.2 ± 5.1%) | 7 (4.6 ± 2.7%) | |
| Anti-CDC5L | 137 | 20 (14.5 ± 4.5%) | 23 (17.1 ± 7.8%) | 31 (22.5 ± 5.4%) | 32 (23.4 ± 3.0%) | 7 (5.0 ± 5.1%) | |